Obeticholic acid (OCA) reached phase 3 clinical trials for the treatment of MASLD with T2D or MASH, where it improved insulin sensitivity, glucose homeostasis, and lipid metabolism, and exerted anti-inflammatory and antifibrotic actions in the liver. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.